A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study

[1]  Y. Sakamoto,et al.  Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer , 2012, British Journal of Cancer.

[2]  R. Labianca,et al.  ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  A. Saga,et al.  Phase II Study of Combined Treatment with Irinotecan and S-1 (IRIS) in Patients with Inoperable or Recurrent Advanced Colorectal Cancer (HGCSG0302) , 2011, Oncology.

[4]  E. Van Cutsem,et al.  Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  I. Hyodo,et al.  Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). , 2010, The Lancet. Oncology.

[6]  M. Shiozawa,et al.  A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer , 2010, Cancer Chemotherapy and Pharmacology.

[7]  M. Asaka,et al.  Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer , 2010, Advances in therapy.

[8]  M. Kusano,et al.  Phase II Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Colorectal Cancer , 2009, Oncology.

[9]  R. Goldberg,et al.  Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials. , 2008, The oncologist.

[10]  W. Scheithauer,et al.  EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Yoshida,et al.  Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer , 2008, International Journal of Clinical Oncology.

[12]  Y. Shimada,et al.  Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Ron Brookmeyer,et al.  A Confidence Interval for the Median Survival Time , 1982 .

[14]  R. Labianca,et al.  Rectal cancer. , 2009, Critical reviews in oncology/hematology.